
Updates from the 2006 annual meeting of the American Society of Clinical Oncology.
Updates from the 2006 annual meeting of the American Society of Clinical Oncology.
Revlimid is approved for certain types of myelodysplastic syndrome, and Sutent was approved for both advanced kidney cancer and gastrointestinal stromal tumor.
Advanced treatments take form for a notoriously hard-to-beat cancer.